Citadel Advisors
AYTU icon

Citadel Advisors’s AYTU BioPharma AYTU Stock Holding History

Citadel Advisors’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-745
Closed -$43K – 13780
2021
Q3 		$43K Sell
745
-670
-47% -$50.3K ﹤0.01% 13438
2021
Q2 		$142K Buy
+1,415
New +$166K ﹤0.01% 12550

Other funds holding AYTU

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Crown Advisors Management Larkspur, California $182M AUM 103.97% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors's AYTU Position: Q2 2026 in Review

Citadel Advisors increased its AYTU BioPharma (AYTU) stake by 34% in Q2 2026, buying an estimated $29.7K and bringing the position to 49,414 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #12653.

Citadel Advisors first reported a position in AYTU in Q1 2018 and has held it in 18 quarters since. The position peaked at $500K in Q4 2020. 38 funds tracked by Wall St. Rank hold AYTU as of Q2 2026.

  • Citadel Advisors held 49,414 shares of AYTU BioPharma worth $106K as of Q2 2026.
  • Citadel Advisors bought 12,573 AYTU BioPharma shares in Q2 2026, an estimated $29.7K.
  • AYTU BioPharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12653 holding.
  • Citadel Advisors first reported a position in AYTU BioPharma in Q1 2018 and has held it in 18 quarters since.
  • Citadel Advisors's AYTU BioPharma position peaked at $500K in Q4 2020.
  • 38 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.